RT Journal Article SR Electronic T1 Antigen concentration, viral load, and test performance for SARS-CoV-2 in multiple specimen types JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.09.12.22279810 DO 10.1101/2022.09.12.22279810 A1 Allison Golden A1 Michelle Oliveira-Silva A1 Hannah Slater A1 Alexia Martines Vieira A1 Pooja Bansil A1 Emily Gerth-Guyette A1 Brandon T. Leader A1 Stephanie Zobrist A1 Alan Kennedy Braga Ferreira A1 Erika Crhistina Santos de Araujo A1 Catherine Duran de Lucena Cruz A1 Eduardo Garbin A1 Greg T. Bizilj A1 Sean J. Carlson A1 Mariana Sagalovsky A1 Sampa Pal A1 Vin Gupta A1 Leo Wolansky A1 David S. Boyle A1 Deusilene Souza Vieira Dall’Acqua A1 Felipe Gomes Naveca A1 Valdinete Alves do Nascimento A1 Juan Miguel Villalobos Salcedo A1 Paul K. Drain A1 Alexandre Dias Costa A1 Dhélio Pereira A1 Gonzalo J Domingo YR 2022 UL http://medrxiv.org/content/early/2022/09/15/2022.09.12.22279810.abstract AB The relationship between N-antigen concentration and viral load within a specimen and across different specimens is essential for interpretation of rapid diagnostic tests (RDT) clinical performance in different use cases. A prospective study was conducted in Porto Velho, Brazil, to investigate RDT performance in different specimen types as a function of the correlation between antigen concentration and viral load. The study included 214 close contacts with recent exposures to confirmed cases, aged 12 years and older and with various levels of vaccination. Antigen concentration was measured in nasopharyngeal swab (NPS), anterior nares swab (ANS), and saliva specimens. Reverse transcriptase (RT)–PCR was conducted on the NPS and saliva specimens, and two RDTs were conducted on ANS and one on saliva. Antigen concentration correlated with viral load when measured in the same specimen type but not across specimen types. Antigen levels were higher in symptomatic cases compared to asymptomatic/oligosymptomatic cases and lower in saliva compared to NPS and ANS samples. Discordant results between the RDTs conducted on ANS and the RT-PCR on NPS were resolved by antigen concentration values. The analytical limit-of-detection of RDTs can be used to predict the performance of the tests in populations for which the antigen concentration is known. The antigen dynamics across different sample types observed in SARS-CoV-2 disease progression support use of RDTs in nasal samples. Given lower antigen concentrations in saliva, tests using saliva is expected to require improved analytical sensitivity to achieve clinical sensitivity similar to testing of nasal samples.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from The Rockefeller Foundation [2020 HTH 039] and Amazon.com [2D-04020007] to Gonzalo J Domingo. Felipe Gomes Naveca and Valdinete Alves do Nascimento were supported by the National Council for Scientific and Technological Development [grant 403276/2020-9] and Inova Fiocruz / Fundacao Oswaldo Cruz [grant VPPCB-007-FIO-18-2-30 - Knowledge generation]. Felipe Gomes Naveca is a National Council for Scientific and Technological Development (CNPq) fellow. Benchmarking work cited and that was used in analysis was funded by the Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/) via grant INV-016821. The funder did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG Institutional Review Board (1301165), the CEPEM ethics committee, and Brazil's National Research Ethics Commission approved this study (44351421.0.0000.0011).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at the Harvard Dataverse https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/NGNUXY